Printer Friendly Printed from http://www.researchandmarkets.com/reports/43047 Abbott Laboratories: Pipeline - Products - Performance - Potential Description: Abbott researches, develops, manufactures and sells a broad and diversified line of healthcare products and services, comprising mainly prescription pharmaceuticals, nutritionals, hospital pharmaceuticals and diagnostics, in more than 130 countries. A major component of Abbott’s operations is its 50:50 joint venture with Takeda, TAP Pharmaceuticals, which mainly markets prescription pharmaceuticals in Japan. Abbott markets pharmaceuticals in the following therapeutic areas: Inflammation and Immunology; Neuroscience and Pain Care; Anti-infectives; Virology; Cardiovascular; Metabolics; Gastrointestinal and Oncology. The company’s research and development efforts are principally focused on Inflammation and Immunology, Neuroscience and Pain Care, Virology, Metabolics and Oncology. In order to strengthen its new product pipeline and reverse the erosion of the company’s growth that has occurred in previous years and most significantly in 2006, Abbott’s senior management team continues to focus on three primary goals: building core franchises in important areas of medicine, leveraging the breadth and diversity of its healthcare businesses to provide solutions for patient and healthcare professionals, and strengthening its scientific capability. Abbott is committed to adding new product lines that are complementary to its existing businesses and will establish it in markets that offer new growth. Its acquisition of the pharmaceutical business of BASF, Perclose, the urology business of Kanoldt and various anaesthesia products from GlaxoSmithKline exemplifies this strategy. To further strengthen the business and sustain success in the Pharmaceuticals segment, Abbott continues to raise investment in pharmaceutical R&D. The pharmaceutical business now has a competitive pipeline and a disciplined decision-making process that is focused on specific therapeutic areas. In addition, the Pharmaceutical Products Group is becoming a globally integrated organisation. Abbott has integrated functions that were separate, such as pharmaceutical research and development, and is continuing to integrate other functions such as manufacturing operations, into a single global structure with common goals and priorities. Abbott has been selling pharmaceuticals for over one hundred years and has firmly established itself as one of the leading players in this market, regularly featuring among the top fifteen companies in terms of pharmaceutical revenue. The year ending 31st December 2006 was a particularly trying period for the company as although sales of several products exceeded the US$1 billion mark, overall sales growth was less than 1 per cent. The most significant development in terms of sales in 2006, was the termination of Abbott’s distribution agreement with Boehringer Ingelheim. Effective 1st January 2006, Abbott ceased to distribute not only Mobic, formerly the second largest selling product in the company’s portfolio, but also Flomax and on 31st March 2006, Abbott also ceased to market Micardis. With the loss of these products, especially Mobic, Abbott has recorded its first year-on-year decline in pharmaceutical sales in recent years. Contents: EXECUTIVE SUMMARY A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis. THERAPEUTIC AREA FOCUS Key product analysis and forecasting Inflammation Humira (adalimumab) Anti-infectives Biaxin/Klacid/Klaricid/Biclar (clarithromycin) Omnicef (cefdinir) Neuroscience Depakote/Epival/Valcote (divalproex sodium) Virology Kaletra (lopinavir+ritonavir) Cardiovascular TriCor (fenofibrate) Anaesthetics Sevorane/Ultane (sevoflurane) Metabolic Synthroid (levothyroxine sodium) Oncology Lupron Depot/Lucrin (leuprolide) Gastrointestinal Prevacid (lansoprazole) OPERATIONAL DATA A wealth of background and detail A full 5-year financial performance assessment Key corporate events Key agreements Infrastructure Subsidiaries and joint ventures Summary: Pharmaceutical company intelligence reports from Espicom provide a full review of the companys activities together with five-year sales forecasts for its key products. The companys financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the companys product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Ordering: Order Online - visit http://www.researchandmarkets.com/reports/43047 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 21/08/2008 21:24:55 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Abbott Laboratories: Pipeline - Products - Performance - Potential Web Address: http://www.researchandmarkets.com/reports/43047 Office Code: OCHGFMNMMTY Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic €895.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 21/08/2008 21:24:55 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World